# Ocrelizumab (Ocrevus)

Source: https://ourhealthnetwork.com/drugs/ocrelizumab
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Ocrelizumab?

Ocrelizumab (brand name: Ocrevus) is a cd20-directed cytolytic antibody. It is prescribed to treat multiple sclerosis. Across the United States, 49 doctors prescribe Ocrelizumab to approximately 342 Medicare patients.

## Brand names

Ocrevus

## Indications

Ocrelizumab is primarily prescribed for the treatment of multiple sclerosis.

## Conditions treated

- [Multiple Sclerosis](https://ourhealthnetwork.com/conditions/multiple-sclerosis)

## Mechanism of action

The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.

## Drug classification

- Established Pharmacologic Class: CD20-directed Cytolytic Antibody [EPC]
- Mechanism of Action class: CD20-directed Antibody Interactions [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

depression, infection, pain in extremity, upper respiratory tract infection

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)